C4 Therapeutics (CCCC) Current Deferred Revenue (2019 - 2026)

C4 Therapeutics has reported Current Deferred Revenue for 8 years, with the latest figure at $25.6 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 45.26% year-over-year to $25.6 million; the trailing twelve-month figure through Mar 2026 stood at $25.6 million (down 45.26% YoY), and the FY2025 full-year result was $28.3 million, up 51.42% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $25.6 million, down from $28.3 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $49.4 million in Q3 2024, with the low at $8.4 million in Q3 2023.
• Average Current Deferred Revenue over 5 years is $29.1 million, with a median of $30.8 million recorded in 2023.
• Year-over-year, Current Deferred Revenue tumbled 75.86% in 2023 and soared 486.62% in 2024.
• Tracing CCCC's Current Deferred Revenue over 5 years: stood at $33.5 million in 2022, then tumbled by 53.84% to $15.5 million in 2023, then advanced by 20.95% to $18.7 million in 2024, then jumped by 51.42% to $28.3 million in 2025, then retreated by 9.78% to $25.6 million in 2026.
• The last three Current Deferred Revenue figures came in at $25.6 million (Q1 2026), $28.3 million (Q4 2025), and $17.1 million (Q3 2025), per Business Quant data.

Peer Comparison